Skip to search formSkip to main contentSkip to account menu

palivizumab

Known as: PALI, Palivizumab [Chemical/Ingredient], anti-RSV 
A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in… 
National Institutes of Health

Related topics

Related topics

14 relations
1 ML palivizumab 100 MG/ML Injection1 ML palivizumab 100 MG/ML Injection [Synagis]Congenital Heart DefectsDrug Allergy

Broader (1)

Antiviral Agents

Narrower (2)

MEDI 493Synagis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention.
Review
2006
Review
2006
Guidelines for the use of palivizumab in infants and young children with congenital heart disease
1 Guideline Preparation and Review Committee, 2 Department of Pediatric Cardiology, Heart Institute of Japan, Tokyo Women ’ s… 
Review
2005
Review
2005
Palivizumab for preterm infants. Is it worth it?
Respiratory syncytial virus infection is an important cause of morbidity. Although palivizumab prophylaxis is widely used, it is… 
2004
2004
Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002
Background. There are few independent, population-based reports that estimate the risk of hospitalization of respiratory… 
2004
2004
Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and…
A patient with respiratory syncytial virus (RSV) infection and severe combined immunodeficiency was studied during a 3-month… 
2003
2003
Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease
New data are emerging on the use of palivizumab as prophylaxis against infection with the respiratory syncytial virus in infants… 
2002
2002
Optimum Dosage Regimen of Palivizumab?
Palivizumab is a humanized, monoclonal antibody used to protect at-risk infants against respiratory syncytial virus (RSV… 
1999
1999
Questions about palivizumab (Synagis)
To the Editor. A humanized monoclonal antibody designed for the prevention of serious disease attributable to respiratory… 
1997
1997
Expression of EcR and USP in Escherichia coli: purification and functional studies.
The functional ecdysteroid receptor complex consists of a nuclear receptor heterodimer of ecdysteroid receptor (EcR) and… 
Review
1972
Review
1972
The PALI and the SLIC systems.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)